-
Allergan, Inc. v. Alcon Laboratories, Inc. et al DC CAFC
- 2:09-cv-00348
- E.D. Tex.
- Filed: 11/06/2009
- Closed: 08/25/2011
- Latest Docket Entry: 08/25/2011
- Judge: T. John Ward
- PACER
1
Plaintiff
4
Defendants
1
Accused
Product
3
Patents-in-Suit
871
Days in
Litigation
-
Allergan, Inc. v. Alcon Laboratories, Inc. et al DC CAFC
- 2:09-cv-00348
- E.D. Tex.
- Filed: 11/06/2009
- Closed: 08/25/2011
- Latest Docket Entry: 08/25/2011
- Judge: T. John Ward
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
Claim | Outcome |
---|---|
All challenged claims |
Enforceable and Valid
Entry 31 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of treating glaucoma or ocular hypertension which comprises topically administering a therapeutically effective amount of a single composition comprising brimonidine at a concentration of about 0.2% by weight and timolol at a concentration
view more
|
Enforceable and Valid
Entry 31 |
Claim # | Claim Text | Outcome |
---|---|---|
4 |
A method of reducing the number of daily topical ophthalmic doses of brimondine administered topically to an eye of a person in need thereof for the treatment of glaucoma or ocular hypertension from 3 to 2 times a day without loss of efficacy,
view more
|
Enforceable and Valid
Entry 31 |
-
Infringement
Alcon Incorporated
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Combigan | US 7,030,149 B2 |
1, 2, 3, 4
|
No infringement
Entry 31
|
Generic Combigan | US 7,320,976 B2 |
1
|
Infringement
Entry 31
|
Generic Combigan | US 7,323,463 B2 | All Asserted Claims |
Infringement
Entry 31
|
Alcon Laboratories Incorporated
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Combigan | US 7,030,149 B2 |
1, 2, 3, 4
|
No infringement
Entry 31
|
Generic Combigan | US 7,320,976 B2 |
1
|
Infringement
Entry 31
|
Generic Combigan | US 7,323,463 B2 | All Asserted Claims |
Infringement
Entry 31
|
Alcon Research Limited
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Combigan | US 7,030,149 B2 |
1, 2, 3, 4
|
No infringement
Entry 31
|
Generic Combigan | US 7,320,976 B2 |
1
|
Infringement
Entry 31
|
Generic Combigan | US 7,323,463 B2 | All Asserted Claims |
Infringement
Entry 31
|
Falcon Pharmaceuticals Limited
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Combigan | US 7,030,149 B2 |
1, 2, 3, 4
|
No infringement
Entry 31
|
Generic Combigan | US 7,320,976 B2 |
1
|
Infringement
Entry 31
|
Generic Combigan | US 7,323,463 B2 | All Asserted Claims |
Infringement
Entry 31
|